Glucagon-like peptide-1 (GLP-1) type obesity drug craze is hot.Demand for Novo Nordisk's Ozempic, Hugo Bee, and Eli Lilly's ...

Key Takeaways, With Data for Maryland FDA approvals vary by drug: There are currently three GLP-1s on the market that the FDA ...

An innovative treatment based on harmine and alpha cells could transform diabetes treatment and reduce insulin dependence ...

Spending reached $4.86 trillion in 2023, a 7.5% increase from 2022 The growth in spending on hospital care was the highest since 1990.

Merck (MRK) secured exclusive rights to develop and sell an oral weight loss drug under a license deal with Hansoh Pharma that could fetch the Chinese biopharmaceutical company up to $2 billion. Merck ...

The US data suggest that the South has seen the greatest shifts, and the highest rate of GLP-1 prescribing per capita.

Blood sugar and insulin levels also depend on the vagus nerve. As blood sugar levels rise, the vagus nerve stimulates the ...

In its latest report, Coresight Research makes six predictions around trends that will transform U.S. retail throughout 2025.

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

Nutraceuticals offer potential health benefits, from migraine relief to cognitive support, but safety and regulatory issues ...

Shares of Viking Therapeutics (VKTX) are down $2.70, or 6%, to $44.00 in pre-market trading following Merck (MRK) and Chinese biopharmaceutical ...

The US Food and Drug Administration (FDA) has issued warning letters to four companies selling unapproved glucagon-like ...